NASDAQ:FOMXFoamix Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Foamix Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.99 0.00 (0.00 %) (As of 03/9/2020) Add Compare Share Today's Range$2.99Now: $2.99▼$2.9950-Day Range$2.99MA: $2.99▼$2.9952-Week Range$1.97Now: $2.99▼$4.84VolumeN/AAverage Volume518,350 shsMarket Capitalization$184.12 millionP/E RatioN/ADividend YieldN/ABeta1.66 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingFoamix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.33, Foamix Pharmaceuticals has a potential upside of 479.7% from its current price of $2.99.Amount of Analyst CoverageFoamix Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesFoamix Pharmaceuticals has received 261 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFoamix Pharmaceuticals has received 274 “underperform” votes. (Add your “underperform” vote.)Community SentimentFoamix Pharmaceuticals has received 51.21% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote “Outperform” if you believe FOMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFoamix Pharmaceuticals does not currently pay a dividend.Dividend GrowthFoamix Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Foamix Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Foamix Pharmaceuticals is held by insiders.Percentage Held by Institutions46.46% of the stock of Foamix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Foamix Pharmaceuticals are expected to grow in the coming year, from ($1.79) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Foamix Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Foamix Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFoamix Pharmaceuticals has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FOMX Previous Symbol CUSIPN/A CIK1606645 Webwww.foamix.com Phone972-8931-6233Debt Debt-to-Equity Ratio0.24 Current Ratio5.72 Quick Ratio5.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.60 million Price / Sales51.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.76Profitability EPS (Most Recent Fiscal Year)($1.70) Net Income$-74,160,000.00 Net MarginsN/A Return on Equity-100.58% Return on Assets-81.39%Miscellaneous Employees80 Outstanding Shares61,580,000Market Cap$184.12 million Next Earnings DateN/A OptionableOptionable Receive FOMX News and Ratings via Email Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter. Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Foamix Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Foamix Pharmaceuticals. How were Foamix Pharmaceuticals' earnings last quarter? Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) posted its quarterly earnings data on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.07. View Foamix Pharmaceuticals' earnings history. What price target have analysts set for FOMX? 3 brokers have issued 1-year price objectives for Foamix Pharmaceuticals' stock. Their forecasts range from $11.00 to $30.00. On average, they anticipate Foamix Pharmaceuticals' stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 479.7% from the stock's current price. View analysts' price targets for Foamix Pharmaceuticals. Has Foamix Pharmaceuticals been receiving favorable news coverage? Media headlines about FOMX stock have been trending very negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Foamix Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Foamix Pharmaceuticals. Who are some of Foamix Pharmaceuticals' key competitors? Some companies that are related to Foamix Pharmaceuticals include Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Beleave (BE) and Beleave (BE). View all competitors. What other stocks do shareholders of Foamix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Foamix Pharmaceuticals investors own include Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Nabriva Therapeutics (NBRV), Viking Therapeutics (VKTX) and AcelRx Pharmaceuticals (ACRX). Who are Foamix Pharmaceuticals' key executives? Foamix Pharmaceuticals' management team includes the following people: Mr. David T. Domzalski, CEO & Director (Age 52)Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)Dr. Iain A. Stuart, Chief R&D Officer (Age 46) What is Foamix Pharmaceuticals' stock symbol? Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX." What is Foamix Pharmaceuticals' stock price today? One share of FOMX stock can currently be purchased for approximately $2.99. How big of a company is Foamix Pharmaceuticals? Foamix Pharmaceuticals has a market capitalization of $184.12 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Foamix Pharmaceuticals employs 80 workers across the globe. What is Foamix Pharmaceuticals' official website? The official website for Foamix Pharmaceuticals is www.foamix.com. How can I contact Foamix Pharmaceuticals? Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
